Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide

NCT02120638 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT02120638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02120638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
Lead sponsor
Huashan Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2014
Completion date
April 30, 2016
Enrollment
100 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

multidrug resistant tuberculosis